RotaTeq (sanofi pasteur/Wistar Institute/Children's Hospital of Philadelphia).
Sanofi pasteur MSD (a joint venture between Merck & Co and sanofi pasteur (formerly Aventis Pasteur)), in collaboration with the Wistar Institute and the Children's Hospital of Philadelphia, is developing RotaTeq, an oral liquid pentavalent vaccine for the potential prevention of rotavirus infection-related disorders, such as infant diarrhea and malabsorption. Phase III trials had commenced by March 2001.
Desselberger
Ulrich
U
UMR 2472 Virologie Moléculaire et Structurale, CNRS, 1 Avenue de la Terrasse, 91198 Gif-sur-Yvette, France. ulrich.desselberger@vms.cnrs-gif.fr
D017322:Clinical Trials, Phase II as Topic; D000075202:Contraindications; D006801:Humans; D012400:Rotavirus Infections / Q000517:prevention & control*; D022243:Rotavirus Vaccines / Q000009:adverse effects / Q000138:chemical synthesis / Q000627:therapeutic use*; D013329:Structure-Activity Relationship; D014613:Vaccines, Attenuated / Q000009:adverse effects / Q000138:chemical synthesis / Q000627:therapeutic use*
C492535:RotaTeq; D022243:Rotavirus Vaccines; D014613:Vaccines, Attenuated